Search Results
May 14, 2026, 08:00 ET Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results
Item 1A, "Risk Factors," in Lucid Diagnostics' most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, "Risk Factors" in any Quarterly Report on Form 10-Q filed by Lucid Diagnostics after its most recent Annual Report. Lucid
More news about: Lucid Diagnostics
May 14, 2026, 08:00 ET Halfpricesoft.com Eliminates Double Entry with ezPaycheck and ezACH Integration
ezACH enables secure and reliable direct deposits. Together, they form a complete payroll processing solution that saves time and boosts productivity.
More news about: Halfpricesoft.com
May 14, 2026, 08:00 ET Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting
systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient
More news about: Genprex, Inc.
May 14, 2026, 08:00 ET Payoneer and Upwork Extend 15-Year Partnership to Power Global Freelance Payments
outcome of any known and/or unknown legal or regulatory proceedings; and (5) other risks and uncertainties set forth in Payoneer's Annual Report on Form 10-K for the period ended December 31, 2025 and future reports that Payoneer may file with the SEC from time to time. Nothing in this press release
More news about: Payoneer
May 14, 2026, 08:00 ET Innovative Eyewear, Inc. Announces Real-Time AI Translated Calls for the Lucyd App
in the forward-looking statements are set forth in the Company's filings with the Securities and Exchange Commission, including its annual report on Form 10-K under the caption "Risk Factors."Investor Relations Contact:Scott PowellSkyline Corporate Communications Group, LLCOffice:
More news about: Innovative Eyewear, Inc.
May 14, 2026, 08:00 ET America's Defense Industry Is Racing to Escape China's Rare Earth Grip
centers on REalloys' Euclid, Ohio facility, where the company already performs metallothermic reduction to convert rare earth oxides into metal and alloy form. Feedstock oxides are expected to come from both recycled magnets and upstream supply agreements before being processed in-house through reduction and
More news about: OilPrice.com
May 14, 2026, 08:00 ET Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award
requirements and needs for additional financing; and other risks described in the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 and in the Company's subsequent SEC filings, which can be obtained on the SEC website at
More news about: Intensity Therapeutics Inc.
May 14, 2026, 08:00 ET Forum Reports First Quarter 2026 Financial Results
in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as well as the supplemental risk factors and other information the Company has or may file with the SEC, including those disclosed under Item 8.01 of the Current Reports on Form 8-K filed by the Company with the
More news about: Forum Markets, Incorporated
May 14, 2026, 07:55 ET Contango Announces Results for the Quarter Ended March 31, 2026
Gold Inc. ("Contango" or the "Company") (NYSE American: CTGO) (TSX: CTGO) announced today that it filed with the Securities and Exchange Commission its Form 10-Q for the quarter ended March 31, 2026 ("Q1-2026").
More news about: Contango Silver & Gold Inc.
May 14, 2026, 07:30 ET Galmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 300mg
achievements to be materially different from those anticipated by the forward-looking statements. We discuss many of these risks in our Annual Report on Form 20-F for the year ended December 31, 2025, filed with the SEC on March 31, 2026 in greater detail under the heading "Risk Factors." Given these uncertainties,
More news about: Galmed Pharmaceuticals Ltd.
May 14, 2026, 07:30 ET Nova Reports Record First Quarter 2026 Financial Results
matters discussed in this press release also involve risks and uncertainties summarized under the heading "Risk Factors" in Nova's Annual Report on Form 20-F for the year ended December 31, 2025, filed with the Securities and Exchange Commission on February 17, 2026. These factors are updated from time
More news about: Nova
May 14, 2026, 07:30 ET Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment
for any of its products or product candidates. These and other risks are described under the caption "Risk Factors" in Karyopharm's Annual Report on Form 10-K for the year ended December 31, 2025, which was filed with the Securities and Exchange Commission (SEC) on February 13, 2026, and in other filings
More news about: Karyopharm Therapeutics Inc.
May 14, 2026, 07:27 ET Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ
include the risks and uncertainties referred to in the Company's Annual Information Form filed with the Canadian securities administrators and U.S. Securities and Exchange Commission (as part of its Annual Report on Form 40-F) on March 31, 2026, available on SEDAR+ at sedarplus.ca and EDGAR at sec.gov,
More news about: Cardiol Therapeutics Inc.
May 14, 2026, 07:10 ET Healthcare Triangle Reports 627% Increase in Gross Profit and 166% Increase in Revenue for Q1 2026
could differ materially from current projections or implied results. Investors should read the risk factors out lined in the company's annual report on form 10-K for the year ended December 31, 2025, on file with the Securities Exchange Commission (the "SEC") and in previous filings, subsequent filings and
More news about: Healthcare Triangle, Inc.
May 14, 2026, 07:10 ET REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights
of Operations" sections of REGENXBIO's Annual Report on Form 10-K for the year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (SEC) and comparable "risk factors" sections of REGENXBIO's Quarterly Reports on Form 10-Q and other filings, which have been filed with the SEC
More news about: REGENXBIO Inc.
May 14, 2026, 07:05 ET Cypherpunk Technologies Reports First Quarter 2026 Financial Results
risks and uncertainties including but not limited to those set forth under the caption "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the SEC, or as may be included in other reports or information we file with the SEC, as well as discussions of potential risks, uncertainties,
More news about: Cypherpunk Technologies Inc.
May 14, 2026, 07:05 ET Cypherpunk Technologies Reports First Quarter 2026 Financial Results
risks and uncertainties including but not limited to those set forth under the caption "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the SEC, or as may be included in other reports or information we file with the SEC, as well as discussions of potential risks, uncertainties,
More news about: Cypherpunk Technologies Inc.
May 14, 2026, 07:03 ET Veeva Commercial Summit to Feature Biopharma's AI Successes and the Path to Agentic Commercial
There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-K for the fiscal year ended January 31, 2026, which you can find
More news about: Veeva Systems
May 14, 2026, 07:01 ET Iridium to Acquire Aireon, Advancing its Strategy to Lead the Future of Aviation Safety
technological factors. Additional factors that could cause actual results to differ materially are described under the caption "Risk Factors" in Iridium's Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission ("SEC") on February 12, 2026, as well as in other filings
More news about: Iridium Communications Inc.
May 14, 2026, 07:01 ET Iridium to Acquire Aireon, Advancing its Strategy to Lead the Future of Aviation Safety
technological factors. Additional factors that could cause actual results to differ materially are described under the caption "Risk Factors" in Iridium's Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission ("SEC") on February 12, 2026, as well as in other filings
More news about: Iridium Communications Inc.
May 14, 2026, 07:00 ET Mezzion Secures Strategic Financing to Support Advancement of Global Phase 3 FUEL-2 Trial in Fontan Patients
confirmatory Phase 3 FUEL-2 clinical trial evaluating udenafil in adolescents and young adults living with Fontan circulation, a serious and life-limiting form of congenital heart disease for which there are currently no approved therapies specifically indicated for Fontan patients."This financing represents
More news about: Mezzion Pharmaceuticals, Inc
May 14, 2026, 07:00 ET REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE® Study of RGX-202
and Results of Operations" sections of REGENXBIO's Annual Report on Form 10-K for the year ended December 31, 2025, and comparable "risk factors" sections of REGENXBIO's Quarterly Reports on Form 10-Q and other filings, which have been filed with the SEC and are available on
More news about: REGENXBIO Inc.
May 14, 2026, 07:00 ET Fermi Inc. Outlines Fermi 2.0 Strategic Evolution and Reports First Quarter 2026 Financial Results
website. A replay of the webcast will be available for a period of one year.SEC FilingsFermi's report on Form 10-Q for the quarter ended March 31, 2026, will be filed with the U.S. Securities and Exchange Commission and made available through the SEC's website
More news about: Fermi Inc.
May 14, 2026, 07:00 ET Boyd Group Services Inc. Election of Directors
reviewing our forward-looking statements, investors and others should refer to the "Business Risks and Uncertainties" section of Boyd's Annual Information Form, the "Business Risks and Uncertainties" and other sections of our Management's Discussion and Analysis of Operating Results and Financial Position and
More news about: Boyd Group Services Inc.